Abstract. We 
The measurement of oestrogens, in particular oestriol, in maternal blood or urine is a widely used test of foetal well-being in late pregnancy (Chard & Klopper 1982) . The basic physiology underlying this practical application was explored in great detail in the 1960's (Diczfalusy & Mancuso 1969; Ryan 1980) and led to the concept of the 'foetoplacental unit': a description of the pro¬ cess by which oestriol is secreted by the placenta from androgenic precursors initially synthesised in the foetal adrenal gland and then further processed by the foetal liver. The existence of the foetal side of this pathway confers a major theo¬ retical advantage to oestrogens as opposed to exclusively placental products such as placental lactogen (hPL) .
Surprisingly, however, this theory has never been put to experimental test. Thus, the evidence that maternal E 3 levels relate to foetal growth and well-being could just as well be the primary result of placental function. The placenta is, after all, the final and probably rate-limiting step in the synthetic pathway. Clinically, the implications of measurement of E3 seem remarkably similar to those of placental products such as hPL (Chard et al. 1985) . To There was a linear correlation between E3 levels in the mother and foetus but none with DHEA-SO4 levels ( It has been proposed that the major factor controlling the secretion of specific proteins from the placenta is uteroplacental blood-flow (Chard 1981) . A similar proposal has been made in re¬ spect of the synthesis of oestrogens from maternal precursors (Senner et al. 1985 (Chard et al. 1985) .
